Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes.
about
Hypoplastic left heart syndrome: current considerations and expectationsThe perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejectionAntibody-mediated rejection: emergence of animal models to answer clinical questionsThe role of donor-specific antibodies in acute cardiac allograft dysfunction in the absence of cellular rejection.Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathyValue of the first post-transplant biopsy for predicting long-term cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patientsSubclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.Antibody-mediated rejection: an evolving entity in heart transplantation.Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo.Association of periarterial neovascularization with progression of cardiac allograft vasculopathy and long-term clinical outcomes in heart transplant recipients.A role for antibodies to human leukocyte antigens, collagen-V, and K-α1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy.Report from a consensus conference on antibody-mediated rejection in heart transplantationSex Related Differences in the Risk of Antibody-Mediated Rejection and Subsequent Allograft Vasculopathy Post-Heart Transplantation: A Single-Center ExperienceHeart transplantation research in the next decade--a goal to achieving evidence-based outcomes: National Heart, Lung, And Blood Institute Working GroupAntibody-mediated rejection in heart transplantation: case presentation with a review of current international guidelinesImproving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury.Management of heart transplant recipients: reference for primary care physicians.Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection.Immunosuppression following heart transplantation: prospects and challenges.Coronary cardiac allograft vasculopathy versus native atherosclerosis: difficulties in classification.Heart transplantation: review.The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions.Immunosuppression and adult heart transplantation: emerging therapies and opportunities.Biomarkers of acute rejection following cardiac transplantation.Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection.Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.New issues in heart transplantation for heart failure.Acute Cellular Rejection and C4d Positivity in Heart Transplantation : A Manifestation of Asymptomatic Antibody-Mediated Rejection?AST Cutting Edge of Transplantation 2013 Meeting Report: a comprehensive look at B cells and antibodies in transplantation.Graft-Infiltrating Macrophages Adopt an M2 Phenotype and Are Inhibited by Purinergic Receptor P2X7 Antagonist in Chronic RejectionAntibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury.Donor-specific antibodies: can they predict C4d deposition in pediatric heart recipients?Evolving concepts and treatment strategies for cardiac allograft vasculopathy.Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation.Molecular Assessment of Microcirculation Injury in Formalin-Fixed Human Cardiac Allograft Biopsies With Antibody-Mediated Rejection.C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients.Donor-specific antibodies are associated with micro- and macrovascular coronary disease, restrictive myocardial damage, and poor outcome in heart-transplanted patients.Corticosteroid wean after heart transplantation-Is there a risk for antibody formation?Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection.Current Expectations for Cardiac Transplantation in Patients With Congenital Heart Disease.
P2860
Q26821904-34D41092-92DB-4F7F-8121-2D215FBCCB84Q26862195-3F2910DA-2460-4014-BF7A-BEF8CCAE9F4DQ27692014-5F637656-51D1-4506-8FA1-0E331C0947BCQ33911449-A6E14273-8712-4A9B-9C5F-327A29CDA960Q34238488-43CD8EC0-A66D-40E8-ACD1-C76405928947Q34257142-9463BD42-15B4-4066-8B46-B4D44CCFD39BQ35790552-8AF0DEA2-2FFB-47D6-B1B3-FB6F4E89A4F3Q35876250-24026D99-2D08-45C2-8B81-1231C83311FAQ36584512-5B7361FF-7DFE-4C80-B07A-2B710F9DE062Q37029903-B9121550-89DB-45DB-A581-06C5D53FEF5CQ37044200-9E0FD875-C342-4D6A-B99B-B6D0AB636DB6Q37313051-C8310F77-EDBA-4AE5-BF50-83FF4D6B3528Q37346571-50640F2D-BD3A-40AA-A57A-E02E036E1F82Q37524481-05EA5205-26B8-44CA-9DBE-F5DBF56EC2A0Q37969113-C5096415-429D-4FFC-8ADA-8ABBA802EF1DQ38032621-5A1D51F4-982E-4DF7-B898-A495D9632E2FQ38036785-055D2CC9-3F24-43D8-B9D7-EFB58C6849ABQ38123309-E65EADE3-D7BE-4E0F-8BB2-A8F4CE0F2529Q38184649-600FFB96-D599-493C-94BF-AE2B7BACD82AQ38210159-8B2E15C3-1955-4D04-811F-7F58AE64EBE5Q38543941-547412E3-26E0-427E-BDCF-FD413B3D8D77Q38793606-059D5B3B-9F9A-4F0A-9014-219942324C9AQ39029380-07417CC7-E8B3-4937-BCAF-BD3F6183BBC1Q39128537-D5B4A958-6CF6-4A38-81C2-4885B00B3656Q39217968-4DAF8899-11A1-4565-AF01-070430622F3FQ39366396-489C6240-73ED-4470-8800-03FF72DBB6EEQ39610198-20F66B25-EA00-4B4A-A497-1C14A5AC3EF4Q40108113-D87790EC-1CBB-408A-AAF2-174084D999AAQ40331013-84E96CE7-3349-4711-89FE-4886E90ECB1AQ41349670-87581206-05D7-4D0E-9A92-604D3F57F248Q41849097-7F862012-02CD-4462-8804-CFFCE2141D4DQ44055243-3D705D9C-4CFB-41C0-82B2-15A4829745B7Q47613394-7C87EC4C-78AE-4C50-AED1-8DF8EF1DA562Q48149010-2B1174EC-036E-4338-853F-96B7D940F42FQ48165787-6E761FBE-AC5D-405C-8530-1D2172892ACDQ48215946-9B15F699-8BC9-4182-9584-A212C349A481Q48259861-2D1C32E3-586A-4332-B67C-48ADBFFB3760Q48297414-B89C6C4D-2534-42BE-A97A-1C2977AED2B9Q50910367-6F599F51-5507-4943-9637-717B961BD1AAQ51102400-A4F31215-98A8-4C06-8254-8944D52FAC65
P2860
Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Asymptomatic antibody-mediated ...... tation predicts poor outcomes.
@en
Asymptomatic antibody-mediated ...... tation predicts poor outcomes.
@nl
type
label
Asymptomatic antibody-mediated ...... tation predicts poor outcomes.
@en
Asymptomatic antibody-mediated ...... tation predicts poor outcomes.
@nl
prefLabel
Asymptomatic antibody-mediated ...... tation predicts poor outcomes.
@en
Asymptomatic antibody-mediated ...... tation predicts poor outcomes.
@nl
P2093
P2860
P1476
Asymptomatic antibody-mediated ...... ntation predicts poor outcomes
@en
P2093
Abbas Ardehali
Elaine F Reed
Grace W Wu
Jignesh K Patel
Krista K Kiyosaki
Michael C Fishbein
Michelle M Kittleson
P2860
P304
P356
10.1016/J.HEALUN.2009.01.015
P577
2009-03-14T00:00:00Z